Semnur Pharmaceuticals, Inc. (SMNR)

Semnur Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	163.18	157.87	2.98	1.64	1.65
Research & Development	4.37	2.55	1.71	1.62	2.12
Operating Expenses	167.55	160.42	4.69	3.26	3.77
Operating Income	-167.55	-160.42	-4.69	-3.26	-3.77
Pretax Income	-167.68	-160.42	-4.69	-3.26	-3.77
Net Income	-167.68	-160.42	-4.69	-3.26	-3.77
Net Income to Common	-167.68	-160.42	-4.69	-3.26	-3.77
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	220	205	200	160	160
Shares Outstanding (Diluted)	220	205	200	160	160
Shares Change	-0.05%	2.39%	25.00%	-	-
EPS (Basic)	-0.76	-0.78	-0.02	-0.02	-0.02
EPS (Diluted)	-0.76	-0.78	-0.02	-0.02	-0.02
EPS Growth	-	-	-	-	-
EBIT	-167.55	-160.42	-4.69	-3.26	-3.77

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 11, 2026

Data Sources Report a data error